• Achieved FY2025 guidance with 8% revenue and EBITDA growth
• Organic revenue growth of 5%, EBITDA margin expansion of 40 bps
• Completed LADR acquisition in Germany, boosting market position

Sonic Healthcare reported a net profit of A$514 million for the year ended 30 June 2025, on revenues of ~A$9.6 billion. The company achieved its full-year guidance range, with EBITDA of A$1,702 million on a Constant Currency basis (A$1,730 million after adjusting for non-recurring items). Sonic delivered 5% organic revenue growth and 40 basis points of EBITDA margin expansion on a normalised basis. The company's management teams are now focused on meeting expectations for FY2026 by driving organic growth, controlling costs, and realizing synergies from recent acquisitions in Switzerland, Germany, and the USA, including the LADR Laboratory Group acquisition completed on 1 July 2025. LADR was one of the 'Top 5' national groups in Germany, with 2024 revenue of €370 million and EBITDA of €50 million. The acquisition is immediately earnings per share accretive for Sonic and offers strong post-synergy returns on investment. Sonic's UK operations achieved 14% organic growth, while Australia grew 6% organically. Germany and Switzerland grew 4% each, and Belgium 2%, but the USA saw (1)% organic growth due to low market growth, a payor contract loss, and disruptions from the Change Healthcare cyber event. Sonic's Radiology division performed very strongly, with 10% organic revenue growth and 12% EBITDA growth. The company remains well-positioned for future earnings growth, driven by strong organic revenue growth, synergy realization, and improving returns from completed acquisitions and contract wins.

FY2026 earnings guidance equates to EPS growth of up to ~19% (using current exchange rates).